DK174871B1 - Amphotericin-B/cholesterolsulfat-sammensætning og fremgangsmåde til fremstilling af samme - Google Patents

Amphotericin-B/cholesterolsulfat-sammensætning og fremgangsmåde til fremstilling af samme Download PDF

Info

Publication number
DK174871B1
DK174871B1 DK198805983A DK598388A DK174871B1 DK 174871 B1 DK174871 B1 DK 174871B1 DK 198805983 A DK198805983 A DK 198805983A DK 598388 A DK598388 A DK 598388A DK 174871 B1 DK174871 B1 DK 174871B1
Authority
DK
Denmark
Prior art keywords
amb
cholesterol
amphotericin
particles
suspension
Prior art date
Application number
DK198805983A
Other languages
Danish (da)
English (en)
Other versions
DK598388D0 (da
DK598388A (da
Inventor
Robert Abra
Original Assignee
Intermune Inc A Delaware Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc A Delaware Corp filed Critical Intermune Inc A Delaware Corp
Publication of DK598388D0 publication Critical patent/DK598388D0/da
Publication of DK598388A publication Critical patent/DK598388A/da
Application granted granted Critical
Publication of DK174871B1 publication Critical patent/DK174871B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
DK198805983A 1987-02-27 1988-10-27 Amphotericin-B/cholesterolsulfat-sammensætning og fremgangsmåde til fremstilling af samme DK174871B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1957587 1987-02-27
US07/019,575 US4822777A (en) 1987-02-27 1987-02-27 Amphotericin B/cholesterol sulfate composition
US8800599 1988-02-26
PCT/US1988/000599 WO1988006450A1 (fr) 1987-02-27 1988-02-26 Procede et composition de sulfate de cholesterol/amphotericine b

Publications (3)

Publication Number Publication Date
DK598388D0 DK598388D0 (da) 1988-10-27
DK598388A DK598388A (da) 1988-10-27
DK174871B1 true DK174871B1 (da) 2004-01-12

Family

ID=21793937

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198805983A DK174871B1 (da) 1987-02-27 1988-10-27 Amphotericin-B/cholesterolsulfat-sammensætning og fremgangsmåde til fremstilling af samme

Country Status (12)

Country Link
US (1) US4822777A (fr)
EP (1) EP0303683B1 (fr)
JP (1) JPH0610134B2 (fr)
AT (1) ATE88348T1 (fr)
AU (1) AU599779B2 (fr)
CA (1) CA1336890C (fr)
DE (1) DE3880397T2 (fr)
DK (1) DK174871B1 (fr)
FI (1) FI884889L (fr)
HK (1) HK80596A (fr)
NO (1) NO884741D0 (fr)
WO (1) WO1988006450A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0825869B2 (ja) * 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US5032582A (en) * 1987-02-27 1991-07-16 Liposome Technology, Inc. Method for treating fungal infections with amphotericin B/cholesterol sulfate composition
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5194266A (en) * 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
JP3074734B2 (ja) * 1990-11-16 2000-08-07 日本新薬株式会社 分散製剤
CA2113272A1 (fr) * 1991-08-14 1993-03-04 Francis J. Martin Methode de traitement du sida par l'amphotericine b a toxicite reduite
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
IT1283149B1 (it) * 1996-07-12 1998-04-07 Prodotti Antibiotici Spa Complessi di n'-dimetilaminoacetilpartricina a dimetilaminoetilamide, o suoi sali, e colesterol 3-solfato
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7473433B2 (en) 2000-12-21 2009-01-06 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
TWI249408B (en) * 2003-12-10 2006-02-21 Ind Tech Res Inst New antifungal formulation and manufacturing method thereof
PL1781604T3 (pl) * 2004-06-23 2014-01-31 Synta Pharmaceuticals Corp Sole bis(tiohydrazydoamidu) do leczenia nowotworów
BRPI0610219A2 (pt) * 2005-04-15 2010-06-08 Synta Pharmaceuticals Corp métodos de tratamento de um ser humano com cáncer e composição de farmacêutica
WO2007021881A1 (fr) * 2005-08-16 2007-02-22 Synta Pharmaceuticals Corp. Formulation de bis(thio-hydrazide amide)
US8609720B2 (en) 2006-08-21 2013-12-17 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US7939564B2 (en) * 2006-08-31 2011-05-10 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
WO2008033494A2 (fr) * 2006-09-15 2008-03-20 Synta Pharmaceuticals Corp. Purification de bis(thiohydrazide amides)
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
DE102015102210A1 (de) 2015-02-16 2016-08-18 Heraeus Medical Gmbh Antimykotischer polymerisierbarer Knochenzement und ein Verfahren zu seiner Herstellung
US20200155583A1 (en) * 2017-02-21 2020-05-21 Ico Therapeutics Inc. Solid oral formulations of amphotericin b
CN110305926B (zh) * 2019-05-27 2021-02-26 浙江工业大学 一种基于两性霉素b代谢途径的发酵方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002741A (en) * 1974-04-24 1977-01-11 Valter Osvaldovich Kulbakh Meglumine complex fungicidal polyene macrolide antibiotic compositions and treatment method
US4468513A (en) * 1980-09-22 1984-08-28 Eli Lilly And Company 2'-N-Acylated and 2'-N-alkylated derivatives of 4-O-substituted-2-deoxystreptamine aminoglycosides
PT78628B (en) * 1984-05-02 1986-06-18 Liposome Co Inc Pharmaceutical composition with reduced toxicity
US4707470A (en) * 1985-05-17 1987-11-17 Smithkline Beckman Corporation Polyene antibiotic emulsion formulation

Also Published As

Publication number Publication date
DE3880397T2 (de) 1993-07-29
WO1988006450A1 (fr) 1988-09-07
CA1336890C (fr) 1995-09-05
FI884889A0 (fi) 1988-10-21
JPH0610134B2 (ja) 1994-02-09
DE3880397D1 (de) 1993-05-27
ATE88348T1 (de) 1993-05-15
AU599779B2 (en) 1990-07-26
NO884741L (no) 1988-10-25
AU1482688A (en) 1988-09-26
FI884889A7 (fi) 1988-10-21
EP0303683A1 (fr) 1989-02-22
HK80596A (en) 1996-05-17
FI884889L (fi) 1988-10-21
EP0303683B1 (fr) 1993-04-21
DK598388D0 (da) 1988-10-27
NO884741D0 (no) 1988-10-25
JPH01502270A (ja) 1989-08-10
US4822777A (en) 1989-04-18
EP0303683A4 (fr) 1989-12-28
DK598388A (da) 1988-10-27

Similar Documents

Publication Publication Date Title
US5194266A (en) Amphotericin B/cholesterol sulfate composition and method
US4822777A (en) Amphotericin B/cholesterol sulfate composition
US5032582A (en) Method for treating fungal infections with amphotericin B/cholesterol sulfate composition
DK175201B1 (da) Kompositioner omfattende antineoplastiske anthracyclinmidler indkapslet i micellulære phospholipidpartikler og fremgangsmåder til fremstilling deraf
AU740111B2 (en) Hyaluronic drug delivery system
CA2288958C (fr) Composition pharmaceutique comprenant des liposomes lyophilises encapsulant un principe actif essentiellement insoluble dans l'eau, et procede de preparation de cette composition
AU775038B2 (en) A liposome composition having resistance to freeze/thaw damage
CN107320716B (zh) 碱性成纤维细胞生长因子囊泡及其制备方法
Chandraprakash et al. Pharmacokinetic evaluation of surfactant vesicle-entrapped methotrexate in tumor-bearing mice
JP2009507049A (ja) リン脂質のポリエチレングリコール誘導体に包み込まれたビンカアルカロイド系制癌剤のナノミセル製剤
AU638245B2 (en) Preparation of liposome and lipid complex compositions
HK1000912B (en) Preparation of liposome and lipid complex compositions
CA1321351C (fr) Mode de deshydratation de preparations vesiculaires en vue d'un stockage de longue duree
Nounou et al. Influence of different sugar cryoprotectants on the stability and physico-chemical characteristics of freeze-dried 5-fluorouracil plurilamellar vesicles
Sirisha et al. Liposomes-the potential drug carriers
AU664857B2 (en) HIV-treatment method with low-toxicity amphotericin B
Soujanya et al. A Review on Novel Vesicular Drug Delivery System: Proniosomes.
Higgins et al. A comparative investigation of glycinebetaine and dimethylsulphoxide as liposome cryoprotectants
WO1992002208A1 (fr) Composition de doxorubicine/liposome stable
CN102579349B (zh) 一种托拉塞米脂质体注射剂
Sivaprasad et al. Innovative Drug Discovery
Kumar Available online through ISSN: 2319-5622 www. jprinfo. com Proniosome: A Preferable Carrier for Novel Drug Delivery System
Nguyen Freeze-drying of ATP entrapped in cationic, low lipid liposomes
HK1026148B (en) Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation

Legal Events

Date Code Title Description
PBP Patent lapsed

Country of ref document: DK